for subcutaneous use Initial U.S. Approval: 2002
adalimumab is a tumor necrosis factor (TNF) blocker indicated for treatment of: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis or Pediatric Uveitis.
Facts about Adalimumab Injection
Proprietary Name: On Request
Active Ingredient(s): Adalimumab Injection
Dosage Forms And Strengths:
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “Adalimumab Injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For Adalimumab Injection
Approved accessible "Adalimumab Injection"
Adalimumab, among others, is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. It is administered by injection under the skin.
Adalimumab is a disease-modifying antirheumatic drug (DMARD) and monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα). Adalimumab was approved for medical use in the United States in 2002. It is on the World Health Organization's List of Essential Medicines. It is available as a biosimilar medication. In 2020, it was the 205th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
Adalimumab, trade name Exemptia, is a potent TNF-inhibitor and anti-inflammatory drug manufactured and promoted by Zydus Group in India. When people have Rheumatoid Arthritis or other inflammatory diseases, it causes over-secretion of TNF, a protein naturally produced in the body, causing inflammation and damage to the joints. Adalimumab works as anti-TNF, blocking over production of TNF and its harmful effects on the body. It helps to reduce inflammation and alleviate the symptoms of arthritis and other joint disorders.
How can 1 go about obtaining Adalimumab Injection?
If Adalimumab Injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
HUM IRA (adalimumab) Injection, Solution for Subcutaneous use Initial U.S. Approval: 2002
ADALIMUMAB Exemptia Solution for subcutaneous use 40 mg/0.8 mL single-use pre-filled syringe 20 mg/0.4 mL single-use pre-filled syringe
- ADALIMUMAB Exemptia Solution for subcutaneous use
- HIGHLIGHTS OF PRESCRIBING INFORMATION
- FDA Approves New Formulation of Hyrimoz Adalimumab Biosimilar
- FDA Approves Adalimumab-adaz High-Concentration Formulation Biosimilar
- FDA Approves Adalimumab Biosimilar for Plaque Psoriasis, Other Chronic Conditions
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398